Literature DB >> 19357284

Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3.

Loreto A Egaña1, Rolando A Cuevas, Tracy B Baust, Leonardo A Parra, Rehana K Leak, Sarah Hochendoner, Karina Peña, Marisol Quiroz, Weimin C Hong, Mario M Dorostkar, Roger Janz, Harald H Sitte, Gonzalo E Torres.   

Abstract

Uptake through the dopamine transporter (DAT) represents the primary mechanism used to terminate dopaminergic transmission in brain. Although it is well known that dopamine (DA) taken up by the transporter is used to replenish synaptic vesicle stores for subsequent release, the molecular details of this mechanism are not completely understood. Here, we identified the synaptic vesicle protein synaptogyrin-3 as a DAT interacting protein using the split ubiquitin system. This interaction was confirmed through coimmunoprecipitation experiments using heterologous cell lines and mouse brain. DAT and synaptogyrin-3 colocalized at presynaptic terminals from mouse striatum. Using fluorescence resonance energy transfer microscopy, we show that both proteins interact in live neurons. Pull-down assays with GST (glutathione S-transferase) proteins revealed that the cytoplasmic N termini of both DAT and synaptogyrin-3 are sufficient for this interaction. Furthermore, the N terminus of DAT is capable of binding purified synaptic vesicles from brain tissue. Functional assays revealed that synaptogyrin-3 expression correlated with DAT activity in PC12 and MN9D cells, but not in the non-neuronal HEK-293 cells. These changes were not attributed to changes in transporter cell surface levels or to direct effect of the protein-protein interaction. Instead, the synaptogyrin-3 effect on DAT activity was abolished in the presence of the vesicular monoamine transporter-2 (VMAT2) inhibitor reserpine, suggesting a dependence on the vesicular DA storage system. Finally, we provide evidence for a biochemical complex involving DAT, synaptogyrin-3, and VMAT2. Collectively, our data identify a novel interaction between DAT and synaptogyrin-3 and suggest a physical and functional link between DAT and the vesicular DA system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357284      PMCID: PMC2846176          DOI: 10.1523/JNEUROSCI.4559-08.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  55 in total

1.  Coupling the iron-responsive element to GFP--an inducible system to study translation in a single living cell.

Authors:  Bernhard Goetze; Barbara Grunewald; Michael A Kiebler; Paolo Macchi
Journal:  Sci STKE       Date:  2003-10-14

Review 2.  Plasma membrane monoamine transporters: structure, regulation and function.

Authors:  Gonzalo E Torres; Raul R Gainetdinov; Marc G Caron
Journal:  Nat Rev Neurosci       Date:  2003-01       Impact factor: 34.870

3.  Development of new pharmacological approaches in Parkinson's disease.

Authors:  A Carlsson
Journal:  Adv Neurol       Date:  1987

4.  Reliable and global measurement of fluorescence resonance energy transfer using fluorescence microscopes.

Authors:  Z Xia; Y Liu
Journal:  Biophys J       Date:  2001-10       Impact factor: 4.033

5.  Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter.

Authors:  Gonzalo E Torres; Ana Carneiro; Katie Seamans; Chiara Fiorentini; Ava Sweeney; Wei-Dong Yao; Marc G Caron
Journal:  J Biol Chem       Date:  2002-11-11       Impact factor: 5.157

6.  Norepinephrine content of various rat organs after chronic administration of desmethylimipramine.

Authors:  J Avni; S Gerson; P R Draskoczy; J J Schildkraut
Journal:  Arch Int Pharmacodyn Ther       Date:  1975-11

Review 7.  DAncing past the DAT at a DA synapse.

Authors:  Stephanie J Cragg; Margaret E Rice
Journal:  Trends Neurosci       Date:  2004-05       Impact factor: 13.837

8.  Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells.

Authors:  Elisabet Hermanson; Bertrand Joseph; Diogo Castro; Eva Lindqvist; Piia Aarnisalo; Asa Wallén; Gerard Benoit; Bastian Hengerer; Lars Olson; Thomas Perlmann
Journal:  Exp Cell Res       Date:  2003-08-15       Impact factor: 3.905

9.  Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy.

Authors:  Tatiana Sorkina; Suzanne Doolen; Emilia Galperin; Nancy R Zahniser; Alexander Sorkin
Journal:  J Biol Chem       Date:  2003-05-13       Impact factor: 5.157

10.  Characterization of synaptogyrin 3 as a new synaptic vesicle protein.

Authors:  Roger Belizaire; Cheryl Komanduri; Kerry Wooten; Ming Chen; Christina Thaller; Roger Janz
Journal:  J Comp Neurol       Date:  2004-03-08       Impact factor: 3.215

View more
  64 in total

1.  The plasma membrane-associated GTPase Rin interacts with the dopamine transporter and is required for protein kinase C-regulated dopamine transporter trafficking.

Authors:  Deanna M Navaroli; Zachary H Stevens; Zeljko Uzelac; Luke Gabriel; Michael J King; Lawrence M Lifshitz; Harald H Sitte; Haley E Melikian
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

2.  Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles.

Authors:  Prashant Mandela; Michelle Chandley; Yao-Yu Xu; Meng-Yang Zhu; Gregory A Ordway
Journal:  Neurochem Int       Date:  2010-02-20       Impact factor: 3.921

3.  Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency.

Authors:  Corina O Bondi; Ameer Y Taha; Jody L Tock; Nelson K B Totah; Yewon Cheon; Gonzalo E Torres; Stanley I Rapoport; Bita Moghaddam
Journal:  Biol Psychiatry       Date:  2013-07-25       Impact factor: 13.382

4.  Ctr9, a Protein in the Transcription Complex Paf1, Regulates Dopamine Transporter Activity at the Plasma Membrane.

Authors:  Stéphanie De Gois; Patrick Slama; Nicolas Pietrancosta; Amaia M Erdozain; Franck Louis; Caroline Bouvrais-Veret; Laurent Daviet; Bruno Giros
Journal:  J Biol Chem       Date:  2015-06-05       Impact factor: 5.157

5.  Analysis of synaptic proteins in the cerebrospinal fluid as a new tool in the study of inborn errors of neurotransmission.

Authors:  Sofia T Duarte; Carlos Ortez; Ana Pérez; Rafael Artuch; Angels García-Cazorla
Journal:  J Inherit Metab Dis       Date:  2011-01-13       Impact factor: 4.982

6.  Concurrent Inhibition of Vesicular Monoamine Transporter 2 Does Not Protect Against 3,4-Methylenedioxymethamphetamine (Ecstasy) Induced Neurotoxicity.

Authors:  Aram B Cholanians; Andy V Phan; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

Review 7.  Examining the complex regulation and drug-induced plasticity of dopamine release and uptake using voltammetry in brain slices.

Authors:  Mark J Ferris; Erin S Calipari; Jordan T Yorgason; Sara R Jones
Journal:  ACS Chem Neurosci       Date:  2013-05-06       Impact factor: 4.418

8.  Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation.

Authors:  Cody A Siciliano; Kaustuv Saha; Erin S Calipari; Steve C Fordahl; Rong Chen; Habibeh Khoshbouei; Sara R Jones
Journal:  J Neurosci       Date:  2017-11-24       Impact factor: 6.167

9.  Chronic Social Isolation Stress during Peri-Adolescence Alters Presynaptic Dopamine Terminal Dynamics via Augmentation in Accumbal Dopamine Availability.

Authors:  Anushree N Karkhanis; Amy C Leach; Jordan T Yorgason; Ayse Uneri; Samuel Barth; Farr Niere; Nancy J Alexander; Jeffrey L Weiner; Brian A McCool; Kimberly F Raab-Graham; Mark J Ferris; Sara R Jones
Journal:  ACS Chem Neurosci       Date:  2018-10-16       Impact factor: 4.418

10.  Structural and Functional Characterization of the Interaction of Snapin with the Dopamine Transporter: Differential Modulation of Psychostimulant Actions.

Authors:  Amaia M Erdozain; Stéphanie De Gois; Véronique Bernard; Victor Gorgievski; Nicolas Pietrancosta; Sylvie Dumas; Carlos E Macedo; Peter Vanhoutte; Jorge E Ortega; J Javier Meana; Eleni T Tzavara; Vincent Vialou; Bruno Giros
Journal:  Neuropsychopharmacology       Date:  2017-09-14       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.